CRISPR Therapeutics experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and Nasdaq drop 10% and 11%, respectively. The recent announcement of the COO’s resignation was likely a contributing factor to the decline, adding uncertainty around the company’s strategic direction….
By Kashish Tandon and Christy Santhosh (Reuters) – Pfizer’s decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said. Oxbryta, one of at least six treatments for the disease, is mostly used in patients with…
By most metrics, the stock market is priced at a premium these days. But that doesn’t mean bargains can’t still be found. Three Motley Fool contributors think they’ve identified dirt-cheap healthcare stocks to buy right now. Here’s why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). You can still…